Original Business Thinking for the Life Sciences

Allan M. Green, MD, PhD, JD, LLC

Attorney at Law
Text Box: Failed clinical trials can cost biotechnology companies tens of millions of dollars and may impair seriously the survivability of a development stage company. These are good reasons to examine the causes of clinical trial failures in the hope of learning from the experience.

Clinical Trials: Avoiding FaiLure

The biotechnology sector can provide markedly above average rates of return for investors with a tolerance for risk, an interest in the frontiers of science, and the willingness to support invention at its earliest and most creative.  

Text Box: Biotechnology: Financial drivers for expansion

We naturally expect  the rate of successful drug development programs to increase with increasing experience and greater resources.  Recent data from the FDA have challenged that expectation.

Big Pharma Productivity Continues to Slide
Text Box: Significant value is built into R&D stage enterprises in steps well before product commercialization. For investors, the interim operating goals that must be sought are those that add significant enterprise value, if achieved.

Early Clinical Results Continue as Key Value Drivers

Market behavior is more often a subject of belief than of clear fact. Surveys have demonstrated that there is significant physician sensitivity to drug pricing when there are therapeutic alternatives. 

Physician Price Sensitivity

As power shifts between the individual provider and the organization and as different relationships emerge between stakeholders in the healthcare system, new questions about the fairness of emerging equilibria will inevitably arise.  

Ethics in the Delivery of Healthcare Services

Insights and Commentary

To contact us call:

1-617-447-5999

#E-mail: amgreen@fdaregs.com